Browsing Tag
ASX:PAR
2 posts
Paradigm Biopharmaceuticals (ASX: PAR) raises A$14m as Phase 3 osteoarthritis trial enters decisive window
Paradigm Biopharmaceuticals has more cash, but Zilosul still needs Phase 3 proof. ASX:PAR now turns from funding risk to data risk.
April 27, 2026
Paradigm Biopharmaceuticals (ASX: PAR) hits key Phase 3 milestone as dosing begins in U.S. and Australia
Paradigm Biopharmaceuticals (ASX: PAR) begins dosing in its pivotal Phase 3 osteoarthritis trial, setting up a mid-2026 data readout that could redefine its future.
September 30, 2025